Risk and prognosis of endometrial cancer after tamoxifen for breast cancer
Risk and prognosis of endometrial cancer after tamoxifen for breast cancer
复制标题
DOI：
10.1016/s0140-6736(00)02677-5
复制
发表时间：
2000-09-09
期刊：
影响因子：
168.9
通讯作者：
van Leeuwen, FE
中科院分区：
文献类型：
--
作者：
Bergman, L;Beelen, MLR;van Leeuwen, FE
背景他莫昔芬增加子宫内膜癌的风险。然而，很少有研究产生了可靠的风险估计的持续时间，剂量，和最近的使用，或解决了子宫内膜癌的预后在他莫昔芬treated women.Methods我们做了一个全国性的病例对照研究后，他莫昔芬用于乳腺癌的子宫内膜癌的风险和预后。从309例乳腺癌后患子宫内膜癌的妇女和860例乳腺癌但无子宫内膜癌的对照组中获得了关于他莫昔芬使用和子宫内膜癌其他危险因素的信息。我们对276例子宫内膜癌患者进行了组织切片检查，并采用免疫组化方法检测了子宫内膜癌组织中三苯氧胺受体状态和p53的过度表达。结果：299例患者中有108例（36.1%）和245例（28.5%）使用了三苯氧胺（相对危险度1.5 [95%CI 1.1-2.0]）。子宫内膜癌的风险随着他莫昔芬使用时间的延长而增加（p
Background Tamoxifen increases the risk of endometrial cancer. However, few studies have produced reliable risk estimates by duration, dose, and recency of use, or addressed the prognosis of endometrial cancers in tamoxifen-treated women.Methods We did a nationwide case-control study on the risk and prognosis of endometrial cancer after tamoxifen use for breast cancer. Information on tamoxifen use and other risk factors for endometrial cancer was obtained from 309 women with endometrial cancer after breast cancer (cases), and 860 matched controls with breast cancer but without endometrial cancer. For 276 cases, we obtained tissue blocks of endometrial cancer to review the diagnosis, and used immunohistochemistry to examine hormone-receptor status and overexpression of p53,Findings Tamoxifen had been used by 108 (36.1%) of 299 cases and 245 (28.5%) controls (relative risk 1.5 [95% CI 1.1-2.0]). Risk of endometrial cancer increased with longer duration of tamoxifen use (p